» Articles » PMID: 40002248

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2025 Feb 26
PMID 40002248
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a complex and heterogeneous hematologic malignancy characterized by clonal evolution, genetic instability, and interactions with a supportive tumor microenvironment. These factors contribute to treatment resistance, disease progression, and significant variability in clinical outcomes among patients. This review explores the mechanisms underlying MM progression, including the genetic and epigenetic changes that drive clonal evolution, the role of the bone marrow microenvironment in supporting tumor growth and immune evasion, and the impact of genomic instability. We highlight the critical insights gained from single-cell technologies, such as single-cell transcriptomics, genomics, and multiomics, which have enabled a detailed understanding of MM heterogeneity at the cellular level, facilitating the identification of rare cell populations and mechanisms of drug resistance. Despite the promise of advanced technologies, MM remains an incurable disease and challenges remain in their clinical application, including high costs, data complexity, and the need for standardized bioinformatics and ethical considerations. This review emphasizes the importance of continued research and collaboration to address these challenges, ultimately aiming to enhance personalized treatment strategies and improve patient outcomes in MM.

References
1.
Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun M . Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clin Cancer Res. 2022; 28(13):2854-2864. PMC: 9250632. DOI: 10.1158/1078-0432.CCR-21-3695. View

2.
Musolino C, Allegra A, Innao V, Allegra A, Pioggia G, Gangemi S . Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediators Inflamm. 2017; 2017:1852517. PMC: 5635476. DOI: 10.1155/2017/1852517. View

3.
Swamydas M, Murphy E, Ignatz-Hoover J, Malek E, Driscoll J . Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol. 2022; 15(1):17. PMC: 8848665. DOI: 10.1186/s13045-022-01234-2. View

4.
Johnson T, Sudha P, Liu E, Becker N, Robertson S, Blaney P . 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma. Nat Commun. 2024; 15(1):4144. PMC: 11099140. DOI: 10.1038/s41467-024-48327-9. View

5.
Cardona-Benavides I, de Ramon C, Gutierrez N . Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells. 2021; 10(2). PMC: 7914805. DOI: 10.3390/cells10020336. View